Previous Study: TRIO 020
Next Study: TRIO 018

Studies & Results

TRIO 019

A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer

View FDA Study View EU Study

Presentations

San Antonio Breast Cancer Symposium, 2015

Hurvitz SA, Andre F, Jiang Z, et al

Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1.

ASCO Annual Meeting, 2015

Slamon DJ, Hurvitz SA, Chen D, et al

Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.

ASCO Annual Meeting, 2012

Hurvitz S, Andre F, Burris HA, et al

BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

Publications

Hurvitz SA, Andre F, Jiang Z, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16:816–829, 2015

von Minckwitz G: A step towards a HER2-positive breast cancer super family. Lancet Oncol 16:745–746, 2015

Toi M, Shao Z, Hurvitz S, et al: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1 BreastCancerResearch (2017) 19:47

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org